Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D04WUA
|
||||
| Former ID |
DNC000469
|
||||
| Drug Name |
CP-101,606
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Parkinson's disease [ICD9: 332; ICD10:G20] | Phase 2 | [521577] | ||
| Therapeutic Class |
Analgesics
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C20H25NO3
|
||||
| Canonical SMILES |
CC(C(C1=CC=C(C=C1)O)O)N2CCC(CC2)(C3=CC=CC=C3)O
|
||||
| InChI |
1S/C20H25NO3/c1-15(19(23)16-7-9-18(22)10-8-16)21-13-11-20(24,12-14-21)17-5-3-2-4-6-17/h2-10,15,19,22-24H,11-14H2,1H3/t15-,19+/m1/s1
|
||||
| InChIKey |
QEMSVZNTSXPFJA-BEFAXECRSA-N
|
||||
| CAS Number |
CAS 847049-30-3
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Glutamate [NMDA] receptor subunit epsilon 2 | Target Info | Antagonist | [535296] | |
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Circadian entrainment | |||||
| Long-term potentiation | |||||
| Glutamatergic synapse | |||||
| Dopaminergic synapse | |||||
| Alzheimer's disease | |||||
| Amyotrophic lateral sclerosis (ALS) | |||||
| Huntington's disease | |||||
| Cocaine addiction | |||||
| Amphetamine addiction | |||||
| Nicotine addiction | |||||
| Alcoholism | |||||
| Systemic lupus erythematosus | |||||
| Pathway Interaction Database | ErbB4 signaling events | ||||
| Reelin signaling pathway | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.